Key facts
- It has raised $14.2M; the latest was Early Stage VC ($14.2M) in Dec 2025.
- Notable investors include Shenzhen Guozhong Venture Capital Management, YuanBio Venture Capital, Hubei Jumpcan Pharmaceutical, Sunz Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ErRuiXinYue Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for ErRuiXinYue Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ErRuiXinYue Technology
Developer of exosome-related technology intended for early diagnosis of neurodegenerative diseases. The company develops exosome-targeted enrichment technology and has developed the world's first automated exosome-targeted enrichment platform that has been applied for multiple domestic and international patents, enabling patients to diagnose and prevent neurodegenerative diseases early.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
ErRuiXinYue Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ErRuiXinYue Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ErRuiXinYue Technology in its N-PORT filings yet. We sweep new filings monthly.